GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Lattice Biologics Ltd (OTCPK:LBLTF) » Definitions » Piotroski F-Score

Lattice Biologics (Lattice Biologics) Piotroski F-Score : 0 (As of May. 28, 2024)


View and export this data going back to 2001. Start your Free Trial

What is Lattice Biologics Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Lattice Biologics has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for Lattice Biologics's Piotroski F-Score or its related term are showing as below:


Lattice Biologics Piotroski F-Score Historical Data

The historical data trend for Lattice Biologics's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lattice Biologics Piotroski F-Score Chart

Lattice Biologics Annual Data
Trend Dec10 Dec11 Dec12 Dec13 Dec14 Sep16 Sep17 Sep18 Sep19 Sep20
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.00 3.00 3.00 6.00 3.00

Lattice Biologics Quarterly Data
Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.00 3.00 3.00 4.00 3.00

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Jun21) TTM:Last Year (Jun20) TTM:
Net Income was -0.239 + -0.269 + -0.389 + -0.026 = $-0.92 Mil.
Cash Flow from Operations was 0.459 + -0.147 + -0.54 + 0.002 = $-0.23 Mil.
Revenue was 0.796 + 0.475 + 0.288 + 0 = $1.56 Mil.
Gross Profit was 0.212 + 0.228 + 0.004 + 0 = $0.44 Mil.
Average Total Assets from the begining of this year (Jun20)
to the end of this year (Jun21) was
(2.479 + 3.018 + 2.869 + 0.632 + 0.606) / 5 = $1.9208 Mil.
Total Assets at the begining of this year (Jun20) was $2.48 Mil.
Long-Term Debt & Capital Lease Obligation was $0.00 Mil.
Total Current Assets was $0.00 Mil.
Total Current Liabilities was $0.51 Mil.
Net Income was -0.668 + -0.07 + -0.854 + -0.32 = $-1.91 Mil.

Revenue was 0.522 + 0.7 + 0.464 + 0.504 = $2.19 Mil.
Gross Profit was -0.118 + 0.4 + 0.262 + 0.147 = $0.69 Mil.
Average Total Assets from the begining of last year (Jun19)
to the end of last year (Jun20) was
(2.928 + 2.275 + 2.475 + 2.336 + 2.479) / 5 = $2.4986 Mil.
Total Assets at the begining of last year (Jun19) was $2.93 Mil.
Long-Term Debt & Capital Lease Obligation was $0.56 Mil.
Total Current Assets was $1.02 Mil.
Total Current Liabilities was $8.05 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Lattice Biologics's current Net Income (TTM) was -0.92. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Lattice Biologics's current Cash Flow from Operations (TTM) was -0.23. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Jun20)
=-0.923/2.479
=-0.37232755

ROA (Last Year)=Net Income/Total Assets (Jun19)
=-1.912/2.928
=-0.65300546

Lattice Biologics's return on assets of this year was -0.37232755. Lattice Biologics's return on assets of last year was -0.65300546. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Lattice Biologics's current Net Income (TTM) was -0.92. Lattice Biologics's current Cash Flow from Operations (TTM) was -0.23. ==> -0.23 > -0.92 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Jun21)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Jun20 to Jun21
=0/1.9208
=0

Gearing (Last Year: Jun20)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Jun19 to Jun20
=0.556/2.4986
=0.22252461

Lattice Biologics's gearing of this year was 0. Lattice Biologics's gearing of last year was 0.22252461. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Jun21)=Total Current Assets/Total Current Liabilities
=0/0.506
=0

Current Ratio (Last Year: Jun20)=Total Current Assets/Total Current Liabilities
=1.021/8.049
=0.12684806

Lattice Biologics's current ratio of this year was 0. Lattice Biologics's current ratio of last year was 0.12684806. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Lattice Biologics's number of shares in issue this year was 128.218. Lattice Biologics's number of shares in issue last year was 99.536. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=0.444/1.559
=0.28479795

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=0.691/2.19
=0.31552511

Lattice Biologics's gross margin of this year was 0.28479795. Lattice Biologics's gross margin of last year was 0.31552511. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Jun20)
=1.559/2.479
=0.62888261

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Jun19)
=2.19/2.928
=0.74795082

Lattice Biologics's asset turnover of this year was 0.62888261. Lattice Biologics's asset turnover of last year was 0.74795082. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+1+1+1+0+0+0+0
=3

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Lattice Biologics has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

Lattice Biologics  (OTCPK:LBLTF) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Lattice Biologics Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Lattice Biologics's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Lattice Biologics (Lattice Biologics) Business Description

Traded in Other Exchanges
N/A
Address
512 East Madison Avenue, Suite A1, Belgrade, MT, USA, 59714
Lattice Biologics Ltd is a biologic product manufacturing company. It manufactures and markets biologic products to domestic and international markets. The products of the company include ADM dermis, DBM Putty, Bone scaffold, and Others, of which key revenue is derived from Bone scaffold. The biologic products are used in various applications such as enhancing fusion in spine surgery, enhancing breast reconstruction post mastectomy for breast cancer patients, sports medicine applications, promotion of bone in foot and ankle surgery, promotion of skull healing following neurosurgery, and subchondral bone defect repair in knee and other joint surgeries. The company generates its revenue from operations principally carried in the United States of America.

Lattice Biologics (Lattice Biologics) Headlines

No Headlines